• Je něco špatně v tomto záznamu ?

A Novel Low-Risk Germline Variant in the SH2 Domain of the SRC Gene Affects Multiple Pathways in Familial Colorectal Cancer

D. Skopelitou, B. Miao, A. Srivastava, A. Kumar, M. Kuświk, D. Dymerska, N. Paramasivam, M. Schlesner, J. Lubiński, K. Hemminki, A. Försti, OR. Bandapalli

. 2021 ; 11 (4) : . [pub] 20210401

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018047

Grantová podpora
COST Action CA17118 European Cooperation in Science and Technology
TRANSCAN ERA-NET Bundesministerium für Bildung und Forschung
856620 Horizon 2020

Colorectal cancer (CRC) shows one of the largest proportions of familial cases among different malignancies, but only 5-10% of all CRC cases are linked to mutations in established predisposition genes. Thus, familial CRC constitutes a promising target for the identification of novel, high- to moderate-penetrance germline variants underlying cancer susceptibility by next generation sequencing. In this study, we performed whole genome sequencing on three members of a family with CRC aggregation. Subsequent integrative in silico analysis using our in-house developed variant prioritization pipeline resulted in the identification of a novel germline missense variant in the SRC gene (V177M), a proto-oncogene highly upregulated in CRC. Functional validation experiments in HT-29 cells showed that introduction of SRCV177M resulted in increased cell proliferation and enhanced protein expression of phospho-SRC (Y419), a potential marker for SRC activity. Upregulation of paxillin, β-Catenin, and STAT3 mRNA levels, increased levels of phospho-ERK, CREB, and CCND1 proteins and downregulation of the tumor suppressor p53 further proposed the activation of several pathways due to the SRCV177M variant. The findings of our pedigree-based study contribute to the exploration of the genetic background of familial CRC and bring insights into the molecular basis of upregulated SRC activity and downstream pathways in colorectal carcinogenesis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018047
003      
CZ-PrNML
005      
20210729104115.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jpm11040262 $2 doi
035    __
$a (PubMed)33916261
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Skopelitou, Diamanto $u Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany $u Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany $u Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany
245    12
$a A Novel Low-Risk Germline Variant in the SH2 Domain of the SRC Gene Affects Multiple Pathways in Familial Colorectal Cancer / $c D. Skopelitou, B. Miao, A. Srivastava, A. Kumar, M. Kuświk, D. Dymerska, N. Paramasivam, M. Schlesner, J. Lubiński, K. Hemminki, A. Försti, OR. Bandapalli
520    9_
$a Colorectal cancer (CRC) shows one of the largest proportions of familial cases among different malignancies, but only 5-10% of all CRC cases are linked to mutations in established predisposition genes. Thus, familial CRC constitutes a promising target for the identification of novel, high- to moderate-penetrance germline variants underlying cancer susceptibility by next generation sequencing. In this study, we performed whole genome sequencing on three members of a family with CRC aggregation. Subsequent integrative in silico analysis using our in-house developed variant prioritization pipeline resulted in the identification of a novel germline missense variant in the SRC gene (V177M), a proto-oncogene highly upregulated in CRC. Functional validation experiments in HT-29 cells showed that introduction of SRCV177M resulted in increased cell proliferation and enhanced protein expression of phospho-SRC (Y419), a potential marker for SRC activity. Upregulation of paxillin, β-Catenin, and STAT3 mRNA levels, increased levels of phospho-ERK, CREB, and CCND1 proteins and downregulation of the tumor suppressor p53 further proposed the activation of several pathways due to the SRCV177M variant. The findings of our pedigree-based study contribute to the exploration of the genetic background of familial CRC and bring insights into the molecular basis of upregulated SRC activity and downstream pathways in colorectal carcinogenesis.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Miao, Beiping $u Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany $u Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
700    1_
$a Srivastava, Aayushi $u Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany $u Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany $u Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany
700    1_
$a Kumar, Abhishek $u Institute of Bioinformatics, International Technology Park, Bangalore 56066, India
700    1_
$a Kuświk, Magdalena $u Department of Genetics and Pathology, Pomeranian Medical University, 71252 Szczecin, Poland
700    1_
$a Dymerska, Dagmara $u Department of Genetics and Pathology, Pomeranian Medical University, 71252 Szczecin, Poland
700    1_
$a Paramasivam, Nagarajan $u Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany
700    1_
$a Schlesner, Matthias $u Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
700    1_
$a Lubiński, Jan $u Department of Genetics and Pathology, Pomeranian Medical University, 71252 Szczecin, Poland
700    1_
$a Hemminki, Kari $u Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany $u Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany $u Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605 Pilsen, Czech Republic
700    1_
$a Försti, Asta $u Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany $u Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
700    1_
$a Bandapalli, Obul Reddy $u Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany $u Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany $u Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany
773    0_
$w MED00203320 $t Journal of personalized medicine $x 2075-4426 $g Roč. 11, č. 4 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33916261 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104114 $b ABA008
999    __
$a ind $b bmc $g 1676513 $s 1138489
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 4 $e 20210401 $i 2075-4426 $m Journal of personalized medicine $n J. pers. med. $x MED00203320
GRA    __
$a COST Action CA17118 $p European Cooperation in Science and Technology
GRA    __
$a TRANSCAN ERA-NET $p Bundesministerium für Bildung und Forschung
GRA    __
$a 856620 $p Horizon 2020
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Možnosti archivace